ClinicalTrials.gg
TerminatedNCT02919072Updated Nov 21, 2023Results posted

Chloroprocaine 3% - Epidural Anesthesia in Unplanned Caesarean Section

A Phase 3 interventional study of Chloroprocaine and Ropivacaine in Unplanned Caesarean Section, sponsored by Sintetica SA. Terminated at 1 site in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Sintetica SA · Phase 3, Interventional, and Treatment

Why this study was terminated
The doctors involved in the study did not enroll any patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The study evaluate the quality of epidural anaesthesia and the safety of Chloroprocaine HCl 3% compared with Ropivacaine HCl 0.75% in patients with an epidural catheter in situ undergoing unplanned Caesarean section.

Read the detailed description

Labouring women who have an epidural catheter in situ and established analgesia, in need of an unplanned Caesarean section, will be randomly allocated to receive either Chloroprocaine HCl 3% (T-group) or Ropivacaine HCl 0.75% (R-group) epidurally. Prior to the epidural injection, the patient will be transferred to the operating theatre. The local anaesthetic solution will be freshly prepared and 20 mL will be administered by epidural injection, according to the standard hospital procedures, as detailed in the "Study Schedule" section below. Time T0 is defined as the start time of the first epidural injection of the investigational product. In case of pain or discomfort, a 6 mL epidural top-up of the same anaesthetic, i.e. Chloroprocaine HCl 3% in T-group and Ropivacaine HCl 0.75% in R-group, will be administered. The anaesthesiologist(s) administering the anaesthetic and collecting the data will be blinded with respect to the treatment given to each patient.

02

Conditions studied

  • Unplanned Caesarean Section
03

In context

Lead sponsor

Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : Signed written informed consent before inclusion in the study (obtained from women fulfilling the criteria, only when effective analgesia has been established)
  2. Sex, pregnancy status and age: Labouring women with singleton pregnancy, ≥ 18 years old
  3. Epidural catheter: Previously sited epidural catheter
  4. : I-II
  5. Analgesia: Effective analgesia established following combined spinal epidural analgesia (CSE)
  6. Term gestation: ≥ 36 weeks
  7. Caesarean section: Unplanned Caesarean section category 2 or 3, according to Lucas Classification
  8. (BMI): ≤ 40 kg/m2
  9. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.

Exclusion criteria

Exclusion Criteria:

  1. Physical findings: abnormal physical findings which could interfere with the objectives of the study. to epidural anaesthesia
  2. : III-V
  3. Further anaesthesia: Patients expected to require further anaesthesia
  4. Epidural catheter: Epidural catheter failure (epidural catheter replacement required or inability to provide effective analgesia)
  5. Pregnancy: Labouring women with multiple pregnancy
  6. Caesarean section: Elective Caesarean section
  7. Allergy: ascertained or presumptive to the active principle and /or formulations ingredients; ascertained or presumptive hypersensitivity to the amide and ester-type anaesthetics
  8. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric diseases, eclampsia, antepartum haemorrhage, sepsis, blood coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure
  9. Medications: Medication known to interfere with the extent of regional blocks (see chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study
  10. Investigative drug studies: participation in the evaluation of any product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
  11. Drug, alcohol: history of drug or alcohol abuse
  12. Plasma cholinesterase: Known plasma cholinesterase deficiency.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Chloroprocaine

    Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.

    Drug: Chloroprocaine

  • Active comparator
    Ropivacaine

    Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.

    Drug: Ropivacaine

Interventions

  • The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.

    Also known as: Ampres

  • The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.

    Also known as: Naropin

06

What researchers measure

Primary outcomes

  1. Time to the Onset of Anaesthesia

    The time from T0 (start time of the epidural injection) to complete loss of cold sensation to the metameric level T4 (block to T4), bilateral.

    Time frame: Up to 1 hour after last epidural injection

Secondary outcomes

  1. Time From T0 to Loss Light Touch Sensation

    Time from T0 to loss light touch sensation to the metameric level T5 (block to T5), bilateral

    Time frame: Up to 1 hour after last epidural injection

  2. Quality of the Block

    Quality of the block assessed between 10 and 20 min after the end of surgery by the anaesthesiologist and patient together using a 0-10 cm visual analogue scale (VAS; 10=excellent anaesthetic quality, 0=very poor anaesthetic quality)

    Time frame: Quality of the block assessed between 10 and 20 minutes after the end of surgery

  3. Maximum Metameric Level of the Sensory Block

    Maximum metameric level of the sensory block assessed by three modalities (complete loss of cold, pinprick and light touch sensation)

    Time frame: Up to 1 hrs after last epidural injection

  4. Motor Block Assessment

    Motor block assessment (modified Bromage scale) at baseline, prior to incision and after surgery

    Time frame: Up to 12 hours after surgery

  5. Proportion of Patients Who Need Top-up Anaesthesia

    Proportion of patients who need top-up epidural anaesthesia (same anaesthetic as first epidural injection)

    Time frame: Up to 2 hours after last epidural injection

  6. Proportion of Patients Who Need Supplementation of Opioids

    Proportion of patients who need supplementation of the block intraoperatively with intravenous opioids

    Time frame: Up to 2 hours after last epidural injection

  7. Proportion of Patients Who Need General Anaesthesia

    Proportion of patients who need general anaesthesia

    Time frame: Up to 2 hours after last epidural injection

  8. Discomfort and Pain During Surgery

    Discomfort and pain assessed during surgery through spontaneous patient's reporting and questioning by the Investigator/anaesthesiologist

    Time frame: Up to 2 hours after last epidural injection

  9. First Breakthrough Pain

    First breakthrough pain assessed by the patient, recorded on a 0-10 cm VAS (0=no pain, 10= most severe pain imaginable)

    Time frame: Up to 12 hours after surgery

  10. Maternal Treatment-emergent Adverse Events

    Maternal treatment-emergent adverse events, with particular attention to pain (see above), pruritus, nausea, vomiting

    Time frame: Up to day 3±1 after surgery

  11. Pulse Rate

    Maternal pulse rate

    Time frame: Up to 12 hours after surgery

  12. Oximetry

    Maternal pulse oximetry (SpO2)

    Time frame: Up to 12 hours after surgery

  13. Electrocardiogram

    Maternal electrocardiogram

    Time frame: Up to 12 hours after surgery

  14. Total Dose of Phenylephrine

    Total dose (μg) of phenylephrine

    Time frame: Up to 2 hours after last epidural injection

  15. Total Dose of Atropine

    Total dose (mg) of atropine

    Time frame: Up to 2 hours after last epidural injection

  16. Intravenous Fluids

    Total volume (ml) of intravenous fluids

    Time frame: Up to 12 hours after surgery

  17. Neonate Apgar

    Neonate Apgar scores at 1 and 5 minutes

    Time frame: 1 and 5 minutes after birth

  18. Foetal Hypoxic Stress

    Indication of foetal hypoxic stress

    Time frame: Up to 12 hours after surgery

  19. Pain at the Site of Surgery

    Pain at the site of surgery at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=most severe pain imaginable)

    Time frame: Up to 12 hours after surgery

  20. Pain at the Site of Epidural Injection

    Pain at the site of epidural injection at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=severe pain)

    Time frame: Up to 12 hours after surgery

  21. Concomitant Medications

    Maternal concomitant medications

    Time frame: Up to day 3±1 after surgery

  22. Neonatal Adverse Events

    Neonatal adverse events

    Time frame: Up to day 3±1 after surgery

07

Results

Posted Nov 21, 2023

Participant flow

Due to difficulties in enrolling patients, the enrolment stopped prematurely, and only 16 patients were screened and randomised (only at site N. 001).

Participant flow — Overall Study
MilestoneChloroprocaineRopivacaine
Started88
Completed88
Not completed00

Outcome measures

PrimaryTime to the Onset of Anaesthesia

The time from T0 (start time of the epidural injection) to complete loss of cold sensation to the metameric level T4 (block to T4), bilateral.

Time frame:
Up to 1 hour after last epidural injection
Reported as:
Mean · minutes
Time to the Onset of Anaesthesia
minutesChloroprocaineRopivacaine
Time to the Onset of Anaesthesia9 ± 5.89.1 ± 4
SecondaryTime From T0 to Loss Light Touch Sensation

Time from T0 to loss light touch sensation to the metameric level T5 (block to T5), bilateral

Time frame:
Up to 1 hour after last epidural injection
Reported as:
Mean · minutes
Time From T0 to Loss Light Touch Sensation
minutesChloroprocaineRopivacaine
Time From T0 to Loss Light Touch Sensation9.3 ± 9.213.3 ± 4.1
SecondaryQuality of the Block

Quality of the block assessed between 10 and 20 min after the end of surgery by the anaesthesiologist and patient together using a 0-10 cm visual analogue scale (VAS; 10=excellent anaesthetic quality, 0=very poor anaesthetic quality)

Time frame:
Quality of the block assessed between 10 and 20 minutes after the end of surgery
Reported as:
Mean · units on a scale
Quality of the Block
units on a scaleChloroprocaineRopivacaine
Quality of the Block9.8 ± 0.48.4 ± 3.7
SecondaryMaximum Metameric Level of the Sensory Block

Maximum metameric level of the sensory block assessed by three modalities (complete loss of cold, pinprick and light touch sensation)

Time frame:
Up to 1 hrs after last epidural injection

Results for this outcome have not been posted.

SecondaryMotor Block Assessment

Motor block assessment (modified Bromage scale) at baseline, prior to incision and after surgery

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryProportion of Patients Who Need Top-up Anaesthesia

Proportion of patients who need top-up epidural anaesthesia (same anaesthetic as first epidural injection)

Time frame:
Up to 2 hours after last epidural injection

Results for this outcome have not been posted.

SecondaryProportion of Patients Who Need Supplementation of Opioids

Proportion of patients who need supplementation of the block intraoperatively with intravenous opioids

Time frame:
Up to 2 hours after last epidural injection

Results for this outcome have not been posted.

SecondaryProportion of Patients Who Need General Anaesthesia

Proportion of patients who need general anaesthesia

Time frame:
Up to 2 hours after last epidural injection

Results for this outcome have not been posted.

SecondaryDiscomfort and Pain During Surgery

Discomfort and pain assessed during surgery through spontaneous patient's reporting and questioning by the Investigator/anaesthesiologist

Time frame:
Up to 2 hours after last epidural injection

Results for this outcome have not been posted.

SecondaryFirst Breakthrough Pain

First breakthrough pain assessed by the patient, recorded on a 0-10 cm VAS (0=no pain, 10= most severe pain imaginable)

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryMaternal Treatment-emergent Adverse Events

Maternal treatment-emergent adverse events, with particular attention to pain (see above), pruritus, nausea, vomiting

Time frame:
Up to day 3±1 after surgery

Results for this outcome have not been posted.

SecondaryPulse Rate

Maternal pulse rate

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryOximetry

Maternal pulse oximetry (SpO2)

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryElectrocardiogram

Maternal electrocardiogram

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryTotal Dose of Phenylephrine

Total dose (μg) of phenylephrine

Time frame:
Up to 2 hours after last epidural injection

Results for this outcome have not been posted.

SecondaryTotal Dose of Atropine

Total dose (mg) of atropine

Time frame:
Up to 2 hours after last epidural injection

Results for this outcome have not been posted.

SecondaryIntravenous Fluids

Total volume (ml) of intravenous fluids

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryNeonate Apgar

Neonate Apgar scores at 1 and 5 minutes

Time frame:
1 and 5 minutes after birth

Results for this outcome have not been posted.

SecondaryFoetal Hypoxic Stress

Indication of foetal hypoxic stress

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryPain at the Site of Surgery

Pain at the site of surgery at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=most severe pain imaginable)

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryPain at the Site of Epidural Injection

Pain at the site of epidural injection at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=severe pain)

Time frame:
Up to 12 hours after surgery

Results for this outcome have not been posted.

SecondaryConcomitant Medications

Maternal concomitant medications

Time frame:
Up to day 3±1 after surgery

Results for this outcome have not been posted.

SecondaryNeonatal Adverse Events

Neonatal adverse events

Time frame:
Up to day 3±1 after surgery

Results for this outcome have not been posted.

Adverse events

Collected over Maternal AEs will be assessed throughout the study from the signature of the informed consent up to follow-up Visit Day 3±1. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chloroprocaine0/8 (0%)0/8 (0%)5/8 (62.5%)
Ropivacaine0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventChloroprocaineRopivacaine
HypotensioVascular disorders5/87/8
procedural painInjury, poisoning and procedural complications1/82/8
anemiaBlood and lymphatic system disorders1/82/8
post lumbar puncture syndromInjury, poisoning and procedural complications1/80/8
POst procedural disconfortInjury, poisoning and procedural complications1/80/8
procedural nauseaInjury, poisoning and procedural complications1/80/8
dysphagiaGastrointestinal disorders0/81/8
vomitingGastrointestinal disorders0/81/8
nauseaGastrointestinal disorders1/81/8
urinary tract infectionInfections and infestations0/81/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)ChloroprocaineRopivacaineTotal
Mean28.8 ± 5.633.3 ± 7.531.05 ± 6.55
Sex: Female, Male
Sex: Female, Male(Participants)ChloroprocaineRopivacaineTotal
Female8816
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ChloroprocaineRopivacaineTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American022
White7613
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ChloroprocaineRopivacaineTotal
Belgium8816
08

Study locations

1 site
  • UZ Leuven, campus Gasthuisberg
    Leuven, 3000, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Jun 2021, 56 months.

Results were first posted in Nov 2023, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2016
First posted
Sep 29, 2016
StartActual
Oct 2016
Primary completionActual
Jun 2021
CompletionActual
Jun 2021
Results first posted
Nov 21, 2023
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02919072
Lead sponsor
Sintetica SA
Collaborators
Cross Research S.A.
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Oct 2016
Primary completion
Jun 2021
Completion
Jun 2021
Results posted
Nov 21, 2023
Last update
Nov 21, 2023

Study contacts

Marc Van de Velde, MD
principal investigator · Department of Anesthesiology, UZ Leuven, campus Gasthuisberg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chloroprocaine

Start the discussion